GROTTOLI, Silvia
 Distribuzione geografica
Continente #
NA - Nord America 5.660
EU - Europa 4.232
AS - Asia 2.435
SA - Sud America 155
OC - Oceania 30
AF - Africa 26
Continente sconosciuto - Info sul continente non disponibili 6
Totale 12.544
Nazione #
US - Stati Uniti d'America 5.522
CN - Cina 1.417
IT - Italia 1.010
SE - Svezia 614
IE - Irlanda 572
UA - Ucraina 437
DE - Germania 353
SG - Singapore 336
FR - Francia 320
FI - Finlandia 272
KR - Corea 247
GB - Regno Unito 220
PL - Polonia 127
JP - Giappone 106
CA - Canada 105
VN - Vietnam 103
BR - Brasile 82
AT - Austria 53
IN - India 51
ES - Italia 45
NL - Olanda 44
RU - Federazione Russa 37
AR - Argentina 32
BE - Belgio 32
MX - Messico 29
UZ - Uzbekistan 29
AU - Australia 24
HK - Hong Kong 24
PH - Filippine 24
TR - Turchia 22
CO - Colombia 20
GR - Grecia 19
CH - Svizzera 15
PT - Portogallo 14
IQ - Iraq 13
CL - Cile 11
MU - Mauritius 11
RO - Romania 11
IL - Israele 9
AE - Emirati Arabi Uniti 8
RS - Serbia 7
TH - Thailandia 7
ID - Indonesia 6
IR - Iran 6
NZ - Nuova Zelanda 6
OM - Oman 6
PE - Perù 6
CZ - Repubblica Ceca 5
EU - Europa 5
SA - Arabia Saudita 5
BT - Bhutan 4
DK - Danimarca 4
EG - Egitto 4
TW - Taiwan 4
BY - Bielorussia 3
HR - Croazia 3
HU - Ungheria 3
BG - Bulgaria 2
CI - Costa d'Avorio 2
CR - Costa Rica 2
DZ - Algeria 2
LT - Lituania 2
LV - Lettonia 2
MY - Malesia 2
QA - Qatar 2
SI - Slovenia 2
TN - Tunisia 2
UY - Uruguay 2
VE - Venezuela 2
AL - Albania 1
AP - ???statistics.table.value.countryCode.AP??? 1
BH - Bahrain 1
ET - Etiopia 1
GE - Georgia 1
GT - Guatemala 1
IM - Isola di Man 1
KE - Kenya 1
LB - Libano 1
LU - Lussemburgo 1
MQ - Martinica 1
MT - Malta 1
PK - Pakistan 1
SC - Seychelles 1
UG - Uganda 1
ZA - Sudafrica 1
Totale 12.544
Città #
Beijing 1.149
Chandler 922
Dublin 562
Houston 492
Jacksonville 260
Singapore 249
Medford 218
Nyköping 217
Torino 210
Ashburn 207
Fairfield 195
Princeton 184
Ann Arbor 172
Dearborn 164
Villeurbanne 159
Wilmington 134
Warsaw 112
Milan 110
Woodbridge 99
Turin 97
Redwood City 96
Boardman 68
Cambridge 67
Dong Ket 64
Seattle 59
Toronto 52
Verona 52
Boston 50
Guangzhou 48
Vienna 48
Santa Clara 43
Fremont 37
Rome 36
Lachine 34
Tokyo 34
Hangzhou 30
Brussels 29
Norwalk 28
Pisa 28
San Mateo 24
Falls Church 23
Hebei 19
Los Angeles 19
Mountain View 19
Pune 19
New York 18
Detroit 17
Nanjing 17
Seoul 17
Hefei 15
Shanghai 15
Kunming 13
San Diego 13
São Paulo 13
Washington 13
Chicago 12
Lappeenranta 12
Melito Di Napoli 12
Mexico 12
Barcelona 11
Central District 11
London 11
Mexico City 11
Munich 11
Santiago 11
Chengdu 10
Modena 10
Munro 10
Nola 10
Philadelphia 10
Istanbul 9
Bogotá 8
Buenos Aires 8
Helsinki 8
Alessandria 7
Florence 7
Hanoi 7
Nanchang 7
Padova 7
Sydney 7
Tappahannock 7
Amsterdam 6
Jinan 6
Muscat 6
Rio De Janeiro 6
Rotterdam 6
San Giuliano Milanese 6
Treviso 6
Ankara 5
Bangalore 5
Berlin 5
Brescia 5
Changchun 5
Duncan 5
Moscow 5
Napoli 5
Novara 5
Phoenix 5
Redmond 5
Renton 5
Totale 7.437
Nome #
Management of GH treatment in adult GH deficiency 1.259
ACROSCORE: a new and simple tool for the diagnosis of acromegaly, a rare and underdiagnosed disease 209
Acylated ghrelin as a provocative test for the diagnosis of GH deficiency in adults. 193
USEFULNESS OF AN AD HOC QUESTIONNAIRE (ACRO-CQ) FOR THE SYSTEMATIC ASSESSMENT OF ACROMEGALY COMORBIDITIES AT DIAGNOSIS AND THEIR MANAGEMENT AT FOLLOW-UP 186
Predictors of morbidity and mortality in acromegaly: an Italian survey. 180
IDENTIFICATION OF RISK CONDITIONS FOR THE DEVELOPMENT OF ADRENAL DISORDERS: HOW OPTIMIZED PUBMED SEARCH STRATEGIES MAKES THE DIFFERENCE 171
Short-term fasting abolishes the sex-related difference in GH and leptin secretion in humans. 171
EARLY ENDOCRINE DYSFUNCTION IN CRITICAL ILLNESS OF DIFFERENT AETIOLOGY 170
Acromegaly is associated with increased cancer risk: a survey in Italy 160
Alprazolam, a benzodiazepine, does not modify the ACTH and cortisol response to hCRH and AVP, but blunts the cortisol response to ACTH in humans. 139
Activation of pituitary axis according to underlying critical illness and its effect on outcome. 130
Arginine counteracts the inhibitory effect of recombinant human insulin-like growth factor I on the somatotroph responsiveness to growth hormone-releasing hormone in humans. 122
L'ipopituitarismo post trauma cranico: dall'età pediatrica all'età adulta 113
Benzodiazepines and anterior pituitary function. 110
The enhancing effect of pyridostigmine on the GH response to GHRH undergoes an accelerated age-related reduction in Down syndrome. 110
Human aging and the GH-IGF-I axis. 109
Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. 106
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. 104
Blunted GH response to growth hormone-releasing hormone (GHRH) alone or combined with arginine in non-insulin-dependent diabetes mellitus. 104
Adrenal responsiveness to high, low and very low ACTH 1-24 doses in obesity. 103
The GH/IGF-I axis in obesity: influence of neuro-endocrine and metabolic factors. 97
DUAL-RELEASE HYDROCORTISONE IN ADDISON’S DISEASE-A REVIEW OF THE LITERATURE 97
Testing pituitary function in aging individuals 97
Effects of alprazolam, a benzodiazepine, on the ACTH-, GH- and PRL-releasing activity of hexarelin, a synthetic peptidyl GH secretagogue (GHS), in patients with simple obesity and in patients with Cushing's disease. 95
Somatotrope responsiveness to Hexarelin, a synthetic hexapeptide, is refractory to the inhibitory effect of glucose in obesity. 92
Alprazolam (a benzodiazepine activating GABA receptor) reduces the neuroendocrine responses to insulin-induced hypoglycaemia in humans. 91
ACROSTUDY: the Italian experience 91
Increased prevalence of impulse control disorder symptoms in endocrine diseases treated with dopamine agonists: a cross-sectional study 91
Metabolic modulation of the growth hormone-releasing activity of hexarelin in man. 88
Endocrine and metabolic response to extreme altitude and physical exercise in athletes. 88
Acylated ghrelin as provocative test for the diagnosis of ACTH deficiency in patients with hypothalamus–pituitary disease 86
Concomitant impairment of GH secretion and peripheral sensitivity in obese patients with obstructive sleep apnea syndrome 86
Early detection of antipituitary antibodies and pituitary dysfunction in patients with severe traumatic brain injury 86
Traumatic Brain Injury as Frequent Cause of Hypopituitarism and Growth Hormone Deficiency: Epidemiology, Diagnosis, and Treatment 86
Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. 84
ADRENAL SENSITIVITY TO ACTH1-24 AS FUNCTION OF AGE, BODY WEIGHT AND PITUITARY FUNCTION 84
First but not second postoperative day growth hormone assessments as early predictive tests for long-term acromegaly persistence 84
Cortistatin-17 and somatostatin-14 display the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma 82
Treatment of acromegaly with SS analogues: should GH and IGF-I target levels be lowered to assert a tight control of the disease? 82
SENSITIVITY AND SPECIFICITY OF DIFFERENT PROVOCATIVE TESTS ASSESSING THE FUNCTION OF HYPOTHALAMO-PITUITARY-ADRENAL (HPA) AXIS IN PATIENTS SUSPECTED FOR SECONDARY HYPOADRENALISM 81
Short-term administration of intranasal or oral Hexarelin, a synthetic hexapeptide, does not desensitize the growth hormone responsiveness in human aging. 80
Effects of chronic slow release-lanreotide treatment on insulin-like growth factor system and metabolic parameters in acromegalic patients 80
ADRENAL SENSITIVITY TO ACTH1-24 AS FUNCTION OF AGE, BODY WEIGHT AND PITUITARY FUNCTION 80
Hypopituitaric patients with corticotropin insufficiency show marked impairment of the cortisol response to ACTH (1-24) independently of the duration of the disease. 80
Progression of pituitary tumours: impact of GH secretory status and long-term GH replacement therapy 80
Three-month treatment with metformin or dexfenfluramine does not modify the effects of diet on anthropometric and endocrine-metabolic parameters in abdominal obesity. 80
GH response to GHRH combined with pyridostigmine or arginine in different conditions of low somatotrope secretion in adulthood: obesity and Cushing's syndrome in comparison with hypopituitarism. 79
Alprazolam, a benzodiazepine, blunts but does not abolish the ACTH and cortisol response to hexarelin, a GHRP, in obese patients. 79
Three-Dimensional Endoscopic Endonasal Approach and Outcomes in Sellar Lesions: A Single-Center Experience of 104 Cases 79
Maximal secretory capacity of somatotrope cells in obesity: comparison with GH deficiency. 79
Assessment of GH/IGF-I axis in obesity by evaluation of IGF-I levels and the GH response to GHRH+arginine test. 77
Age-related endocrine and metabolic changes in simple obesity. 77
Growth hormone levels in the diagnosis of growth hormone deficiency in adulthood. 76
Effect of galanin on basal and stimulated secretion of prolactin, gonadotropins, thyrotropin, adrenocorticotropin and cortisol in humans. 74
Update on epidemiology, etiology, and diagnosis of adult growth hormone deficiency 74
The effects of altitude on the hormonal response to physical exercise 74
Retrospective observational analysis of non-irradiated non-functioning pituitary adenomas 74
Cost-of-illness study in acromegalic patients in Italy. 74
Diagnostic reliability of a single IGF-I measurement in 237 adults with total anterior hypopituitarism and severe GH deficiency. 72
[Growth hormone and lipids] 72
Assessment of the awareness and management of sleep apnea syndrome in acromegaly. The COM.E.TA (Comorbidities Evaluation and Treatment in Acromegaly) Italian Study Group 72
Untreated adult GH deficiency is not associated with the development of metabolic risk factors: a long-term observational study 71
Growth hormone/insulin-like growth factor I axis, glucose metabolism, and lypolisis but not leptin show some degree of refractoriness to short-term fasting in acromegaly 70
Diagnosis of adult GH deficiency 69
Insulin-like growth factor I levels and the diagnosis of adult growth hormone deficiency 68
Early copeptin determination allows prompt diagnosis of post-neurosurgical central diabetes insipidus 68
Comparisons among old and new provocative tests of GH secretion in 178 normal adults. 67
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index 67
Court dwarfs: an overview of European paintings from fifteenth to eighteenth century. 67
The inhibitory effect of glucose on growth hormone secretion is lost in obesity but not in hypertension. 66
Effect of arginine and pyridostigmine on the GHRH-induced GH rise in obesity and Cushing's syndrome. 66
EFFECTS OF ALPRAZOLAM, A BENZODIAZEPINE, ON THE GH, ACTH, CORTISOL AND CATECHOLAMINE RESPONSES TO INSULIN-INDUCED HYPOGLYCEMIA IN HUMANS 66
Hypopituitarism following brain injury: when does it occur and how best to test? 65
Pegvisomant in acromegaly: why, when, how. 64
Endocrinology and Art--Väinö Myllyrinne: the world's tallest acromegalic soldier on a postcard. 64
Three-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diThree-hour spontaneous GH secretion profile is as reliable as oral glucose tolerance test for the diagnosis of acromegaly. 64
The adrenal sensitivity to ACTH stimulation is preserved in anorexia nervosa 62
Galanin positively modulates prolactin secretion in normal women. 62
Acromegaly and joint pain: is there something more? A cross-sectional study to evaluate rheumatic disorders in growth hormone secreting tumor patients 62
Obstructive sleep apnea syndrome impairs insulin sensitivity independently of anthropometric variables 61
Effects of glucose, free fatty acids or arginine load on the GH-releasing activity of ghrelin in humans. 61
Retesting the childhood-onset GH-deficient patient 61
Ghrelin and anterior pituitary function 61
Relationships between IGF-I and age, gender, body mass, fat distribution, metabolic and hormonal variables in obese patients. 60
Effects of glucose load and/or arginine on insulin and growth hormone secretion in hyperprolactinemia and obesity. 59
First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous medical Education) Study Group. 58
Functioning and non-functioning pituitary adenomas in 173 adult and elderly patients 58
EFFECTS OF CORTISTATIN-17 AND SOMATOSTATIN-14 ON ACTH AND CORTISOL HYPERSECRETION IN PATIENTS WITH CUSHING’S DISEASE 57
Acromegalia e gravidanza: quali rischi per la madre e per il feto 57
Biliary adverse events in acromegaly during somatostatin receptor ligands: predictors of onset and response to ursodeoxycholic acid treatment 57
Systemic steroids in patients with COVID-19: pros and contras, an endocrinological point of view 57
Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans 57
Development and Internal Validation of a Predictive Model for Adult GH Deficiency Prior to Stimulation Tests 57
A New Clinical Model to Estimate the Pre-Test Probability of Cushing's Syndrome: The Cushing Score 57
In obesity, glucose load loses its early inhibitory, but maintains its late stimulatory, effect on somatotrope secretion. 56
Normal development of lymphokine activated killing (LAK) in peripheral blood lymphocytes from hyperprolactinemic patients. 56
Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinaemic patients. 56
Microalbuminuria in insulin sensitivity in patients with growth hormone-secreting pituitary tumor 56
IGFs and IGFBPs in adult growth hormone deficiency. 55
Association of craniopharyngioma and pituitary adenoma. 55
Totale 9.729
Categoria #
all - tutte 41.224
article - articoli 0
book - libri 0
conference - conferenze 1.693
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 42.917


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.605 0 0 122 156 169 385 177 103 196 124 122 51
2020/20211.612 128 58 132 72 191 66 173 117 179 169 122 205
2021/20221.706 50 87 90 71 117 90 118 90 70 116 379 428
2022/20232.726 310 209 41 290 237 685 193 146 308 73 164 70
2023/20241.121 164 199 52 68 59 103 43 77 21 63 98 174
2024/2025330 24 262 44 0 0 0 0 0 0 0 0 0
Totale 13.068